CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- 4 Grant or award Co-Chief Executive Officer acquired 60,039 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 21,284 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 22,807 shares (grant or award)
- 4 Grant or award Co-Chief Executive Officer acquired 60,039 shares (grant or award)
- 8-K Event Material agreement
- 424B5 Offering Prospectus
- 424B5 Offering Prospectus
- 8-K Event Other events
- 8-K Event Regulation FD disclosure · Other events
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Planned sale Chief Legal Officer sold 30,000 shares at an average $17.96 ($538,868)
- 144 Insider Sale of Securities
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 8-K Event Shareholder vote results
- 4 Open-market buy Director bought 3,800 shares at $13.51 ($51,338)
Page 2 of 23 · 443 filings